Beam Therapeutics Appoints Sravan Emany as CFO-March 2024-www.financetom.com

Beam Therapeutics Appoints Sravan Emany as CFO

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Beam Therapeutics Appoints Sravan Emany as CFO

Dec 6, 2024 4:41 AM

07:26 AM EST, 12/06/2024 (MT Newswires) -- Beam Therapeutics ( BEAM ) said Friday it has appointed Sravan Emany as chief financial officer, succeeding Terry-Ann Burrell who left the company in August.

Emany's term becomes effective Dec. 19.

Emany was previously CFO and chief operating officer of Ironwood Pharmaceuticals.

Previous page： Lyft and Payfare Ink Long Term Extension of Lyft Direct Program Next page： Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Lyft and Payfare Ink Long Term Extension of Lyft Direct Program

Jul 25, 2024

08:19 AM EDT, 07/25/2024 (MT Newswires) -- Payfare ( PYFRF ) , a digital banking solution company targeting workforces, on Thursday announced the long-term extension of their partnership on Lyft Direct. Lyft Direct, powered by Payfare ( PYFRF ), is a mobile banking solution designed specifically for drivers on the Lyft platform. It offers free instant access to earnings after...

Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand

Jul 25, 2024

On Thursday, Sanofi SA ( SNY ) reported a second-quarter business operating income of 2.8 billion euros ($3.03 billion), up 3.2% year-over-year and 8.3% in constant currency. The company reported second-quarter sales of $11.57 billion (10.75 billion euros), beating the consensus of $11.37 billion. Sales increased 7.8% year over year and 10.2% on constant currency. Also Read: Europe Approves Sanofi/Regeneron’s Dupixent...

NYSE short interest down slightly in mid-July

Jul 25, 2024

July 25 (Reuters) - Short interest on the New York Stock Exchange slipped in mid-July, the exchange said on Wednesday. As of July 15, short interest decreased 0.4% to about 16.14 billion shares, compared with 16.21 billion shares as of late June. Investors who sell securities short borrow shares and then sell them, expecting the stock to fall so they...

Darling Ingredients Fiscal Q2 Earnings, Net Sales Fall

Jul 25, 2024

08:15 AM EDT, 07/25/2024 (MT Newswires) -- Darling Ingredients ( DAR ) reported fiscal Q2 earnings Thursday of $0.49 per diluted share, down from $1.55 a year earlier. Analysts surveyed by Capital IQ expected $0.36. Net sales for the quarter ended June 29 were $1.46 billion, down from $1.76 billion a year earlier. Analysts surveyed by Capital IQ expected $1.46...